)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Mereo Biopharma (MREO) investor relations material
Mereo Biopharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Focused on rare disease therapeutics, with late-stage candidates setrusumab (OI) and alvelestat (AATD-LD); setrusumab Phase 3 studies progressing with final data expected by end of 2025.
Alvelestat advancing toward Phase 3, with ongoing partnering discussions and regulatory alignment achieved.
Achieved $0.5M milestone payment for leflutrozole; no product sales revenue recognized.
Collaboration with Ultragenyx continues for setrusumab, including up to $245M in potential milestones and royalties; manufacturing and supply agreements in place.
Cash position of $56.1M as of June 30, 2025, expected to fund operations into 2027.
Financial highlights
Revenue of $0.5M for Q2 2025 from a one-time milestone; no revenue in Q2 2024.
Net loss of $14.6M for Q2 2025, compared to $12.3M in Q2 2024, impacted by a $5.4M foreign currency loss.
R&D expenses increased to $5.4M in Q2 2025 (up $0.4M YoY), mainly due to setrusumab program costs.
General and administrative expenses decreased to $5.5M in Q2 2025 (down $2.4M YoY), reflecting lower professional fees and ADR reimbursements.
Cash and cash equivalents declined to $56.1M from $69.8M at year-end 2024.
Outlook and guidance
Cash runway expected to fund operations, clinical trials, and capital expenditures into 2027 under current plans.
Additional external funding will be needed to complete development and potential commercialization.
Ongoing focus on advancing setrusumab and alvelestat, with key clinical milestones anticipated by end of 2025.
Alvelestat Phase 3 study preparation ongoing, with regulatory alignment achieved.
Detail EU pre-commercial strategy for setrusumab.
Alvelestat partnership impact on cash runway?
Explain setrusumab R&D expense drivers.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Mereo Biopharma earnings date
Q3 202512 Nov, 2025
Next Mereo Biopharma earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Mereo Biopharma Group plc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases and oncology. The company has a diverse portfolio of product candidates in various stages of clinical development, including treatments for conditions such as osteogenesis imperfecta, Alpha-1 anti-trypsin deficiency, and different types of cancer. Among its leading candidates are etigilimab, an antibody designed for tumor treatment, and alvelestat, intended for Alpha-1 anti-trypsin deficiency. Founded in 2015, Mereo Biopharma Group plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage